The legal team representing Luigi Mangione, the 28-year-old accused of fatally shooting UnitedHealthcare CEO Brian Thompson on a Manhattan street in 2024, abruptly withdrew plans Thursday to pursue a psychiatric defense at his upcoming state trial — reversing course just one day after signaling that strategy to the court.
Why It Matters
The sudden reversal leaves Mangione’s defense posture uncertain as a September trial date approaches. Thompson, a father of two, was killed in what prosecutors have characterized as a premeditated act. The case drew widespread national attention and has raised broader questions about public sentiment toward the health insurance industry.
Mangione has pleaded not guilty to murder charges. A federal prosecution is expected to follow the state proceeding, meaning his legal exposure extends well beyond the outcome of the September trial.
What Happened
At a Wednesday hearing, Mangione’s attorneys confirmed he had undergone a psychiatric evaluation and indicated that an “extreme emotional disturbance” argument would form part of the defense strategy. Under New York law, such a claim can serve as an affirmative defense to reduce a murder charge, though it does not result in acquittal.
The following day, lead attorney Karen Friedman Agnifilo communicated the withdrawal of that plan through a single line in a letter to Manhattan Judge Gregory Carro — offering no public explanation for the decision.
The shift created immediate complications. Judge Carro had ordered the defense to share the results of Mangione’s psychiatric evaluation with prosecutors. Assistant Manhattan District Attorney Joel Seidemann told the court that his office had received no such information from the defense team.
Judge Carro had initially signaled that court documents related to the psychiatric defense strategy would be made publicly available. He reversed that position Thursday, ordering the materials kept under seal.
By the Numbers
- 28 — Mangione’s age at the time of the alleged offense
- 2024 — year Brian Thompson was killed in Manhattan
- 2 — children Brian Thompson is survived by
- September 2026 — scheduled start of state trial
- 1 day — time between defense signaling psychiatric strategy and withdrawing it
Legal Context
The rapid reversal has drawn scrutiny from legal analysts. Gary Galperin, a former Manhattan prosecutor, said the reasons behind the withdrawal remain unclear. “One can only speculate at this point as to the reasons,” Galperin said. “What remains, of course, at this point is the question of what defense they will pursue at trial.”
Legal observers note that abandoning an extreme emotional disturbance argument does not necessarily leave the defense without options, but it narrows the path to avoiding a first-degree murder conviction under New York law. The defense could still contest intent, challenge the prosecution’s evidence, or pursue other legal theories without invoking a formal psychiatric claim.
The sealed documents complicate public understanding of what the evaluation found and why attorneys chose to walk away from it so quickly after signaling its use.
What’s Next
The state trial is scheduled to begin in September before Judge Carro in Manhattan. If convicted on the most serious charges, Mangione faces significant prison time under New York law. A separate federal case is expected to proceed after the state proceedings conclude, adding a second layer of legal jeopardy.
Friedman Agnifilo has not publicly explained what defense strategy will replace the psychiatric approach. Court watchers expect the coming weeks to bring additional pretrial motions that may clarify the direction the defense intends to take.
The Thompson family has not made public statements about Thursday’s developments. UnitedHealthcare, the company Thompson led, has also not commented on the shift in defense strategy.